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The aim of this study was to investigate the effect of intramammary infusions of natural composition GLP 810 with
immunomodulating properties on the local nonspecific cellular and humoral immune response in cows with subclinical mastitis.
The composition GLP 810 consists of lactic acid, lysozyme, glycopeptides, and 0.9% solution of NaCl. The following parameters
were studied: (1) leukocyte differential distribution in milk, (2) expression of cytokines in milk leukocytes, (3) antibacterial
activity, and (4) milk quality. Nineteen mammary glands in five lactating cows were infused with 10mL of GLP 810, and
nineteen other glands from five control cows were treated with 10mL 0.9% NaCl. The results showed that after intramammary
administration of the composition GLP 810 three times with 48 h intervals, the following effects on leukocyte populations in
milk were observed: (1) an increase in the number of polymorphonuclear leukocytes and lymphocytes and (2) a decrease in the
number of macrophages. A reduction in the number of pathogenic bacteria was also detected. The analyses of tumour necrosis
factor-alpha, interleukin-10, and beta-defensin-2 revealed that the production of the aforementioned cytokines significantly
increased, whereas no significant effects on interleukin-1 and caspase-6 expression in milk leukocytes were recorded. However,
there were significant differences between mammary glands with high and low milk somatic cell count. The results suggest that
the composition GLP 810 has an immunomodulatory effect on mammary glands and it could be used for improving the
immune response in cows with subclinical mastitis during lactation.
1. Introduction
Mastitis or udder inflammation is a disease of major eco-
nomic importance in dairy industry worldwide as discussed
elsewhere [1, 2]. Subclinical mastitis is a particular condition
of the mammary gland characterized by a long-term low-
intensity infection and subsequent damage of the mammary
gland tissue resulting in changes to milk composition. The
animal immune status plays a key role in the development
of mastitis after an invasion of bacteria into mammary
glands; therefore, the maintenance of animal health by
encouraging the natural immunological defence including
the use of immunomodulators could serve as an important
alternative to antibiotic therapy. Predominantly, the treat-
ment of mastitis is still based on the use of antibiotics, but,
according to Gyles [3] and Persoons with coauthors [4], the
overall cost of this treatment is fairly expensive, whilst its
effectiveness is constantly decreasing and is associated with
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significant harm to public health since the presence of residues
in milk can promote development of antibiotic resistance.
The fight against the development of bacterial resistance
is based on prudent and rational use of antibiotics, and it is
a priority task in the human health sector and veterinary
medicine worldwide, but alternative methods for the treat-
ment of mastitis are needed to carry out this task. The
authors have shown that the use of natural substances such
as lactoferrin [5], nisin [6], lacticin [7], and probiotic lactoba-
cilli [8–10] is also effective in the treatment of bovine masti-
tis. The aim of this study was to investigate the effect of
intramammary infusions of natural composition GLP 810
with immunomodulating properties on the local nonspecific
cellular and humoral immune response in cows with subclin-
ical mastitis.
2. Materials and Methods
2.1. Composition GLP 810. The immunomodulatory compo-
sition GLP 810 (PCT patent WO2017010856A1) used in this
study was prepared at the Institute of Microbiology and
Virology of Riga Stradins University, and the following
ingredients were included in each single dose of this prepara-
tion: lactic acid 500mg, lysozyme 300mg, glycopeptide from
Lactobacillus helveticus 10mg, and 0.9% sodium chloride
solution in water 10mL.
2.2. Animals and Experimental Design. Ten Holstein and Lat-
vian Brown dairy cows in the middle lactation period of their
2nd or 3rd parity were used. Their average 305-day yield was
8,000 kg. The herd consisted of 320 dairy cows housed in
tie-stall arrangement and milked twice a day. The cows
involved in this study were subclinically infected in one or
two mammary glands—six out of nineteen lactating mam-
mary glands in each cow group had mastitis causing elevated
somatic cell count (SCC) greater than or equal to 400,000 per
mL in each individual cow’s composite milk. All the cows
included in this study had an increased somatic cell count
at least for two consecutive months. No cow had received
any drug-related intervention at least 30 days prior to the
treatment start date. No cow had a history of concurrent dis-
ease other than subclinical mastitis and had no clinically sig-
nificant findings. On the start of the study, no cow had any
visible change in visual milk properties. The unit of study
was mammary gland. Nineteen mammary glands in the
experimental cow group were infused with 10mL of compo-
sition GLP 810 three times at 48 h intervals (1st, 3rd, and 5th
days). Nineteen mammary glands in the control cow group
were treated with 10mL of 0.9% NaCl solution at the same
time as the experimental group. Infusions were carried out
in the morning after milking from 4 : 00 to 6 : 00 a.m. The
clinical assessment of cow health status was carried out daily
from the 1st to the 7th days, as well as on the day 14, marking
the changes in the following parameters: systemic changes
(body temperature, milk yield, and appetite), clinical appear-
ance of the mammary glands (redness, hardness, pain, swell-
ing, and heat), and the visual appearance of the milk (flakes,
clots, and watery appearance). Both the control solution and
the immunomodulatory composition were infused through
the teat canal using an individual single-use teat cannula J-
12 (Jorgensen Laboratories, USA) for each mammary gland.
Before the infusion, the teat was scrubbed with a pad soaked
in 70% ethanol; then, four to six streams of milk were drawn
and discarded, and disinfection was repeated. After the infu-
sion of the solution, udder massage in the upward direction
was carried out to facilitate an even dispersal of the solution
into the mammary gland. Teats were dipped in an iodine dis-
infectant solution by performing routine udder hygiene mea-
sures. Quarter milk samples from all cows were aseptically
collected from each mammary gland 5 times, i.e., prior to
the treatment (1st d) and on the 3rd, 5th, 7th, and 14th days
after the first infusion. In total, 426 milk samples for this
study were obtained and the following examinations were
performed: bacteriological examination, differential counting
of somatic cells, immunocytochemical analysis, and milk
quality studies.
The study was restricted to routine on-farm observations
and measurements, including milk sample collection that did
not inconvenience or stress the animals. The composition
GLP 810, that was used, included solely registered ingredients.
2.3. Bacteriological Examination. Microbiological examina-
tions were carried out at the Microbiology Laboratory of
the Institute of Food and Environmental Hygiene of the
Latvia University of Life Sciences and Technologies, Faculty
of Veterinary Medicine (LLU VMF). Bacterial examination
analyses included evaluation of the total number of
mastitis-causing (pathogenic) bacteria and bacterial clear-
ance, i.e., absence of growth of the bacteria in milk.
Enumeration of staphylococci was performed in accor-
dance with the standard LVS EN ISO 6888-1:1999/A1:2003
“Microbiology of food and animal feeding stuffs—Horizontal
method for the enumeration of coagulase-positive staphylo-
cocci (S. aureus and other species)—Part 1: Technique using
Baird-Parker agar medium—Amendment 1: Inclusion of
precision data”. We confirmed the identification of S. aureus
with the diagnostic reagent “Staphytect Plus” (Oxoid, UK),
where a positive reaction (confirmed S. aureus), according
to the manufacturer’s instructions, was a formation of mac-
roscopically visible flakes. For isolates of coagulase-negative
staphylococci, identification was carried out to a species level
using BBL Crystal Gram-Positive ID (Becton, Dickinson and
Company, USA) and MALDI Biotyper (Bruker, DE) as per
the manufacturer’s instructions. The enumeration of bacteria
of the family Enterobacteriaceae was carried out by a pour
plate technique in accordance with the standard LVS ISO
21528-2:2007 “Microbiology of food and animal feeding
stuffs—Horizontal methods for the detection and enumera-
tion of Enterobacteriaceae—Part 2: Colony-count method”.
E. coli detection was carried out in accordance with a previ-
ously described technique [11]. Isolation of Streptococcus
and Enterococcus spp. bacteria was performed following UK
Standards for Microbiology Investigations [12]. Additionally,
the PathoDxtra Strep Grouping Kit for the Lancefield group
(A, B, C, D, F, and G) Streptococcus spp. identification was
used according to the manufacturer’s instructions (Oxoid,
UK). The determination of lactic acid bacteria (Lactobacillus
spp.) was performed according to the method described by
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the authors [11]. This method is based on the requirements
of standard ISO 15214: 1998 “Microbiology of food and
animal feeding stuffs—Horizontal method for determina-
tion of mesophilic lactic acid bacteria—Colony count
method at 30°C”.
2.4. Differential Counting of Somatic Cells. Differential
counting of the milk smears was performed according to
the methodology described by the authors [13] to specify
the belonging to leukocyte populations. This investigation
also was conducted at the Microbiology Laboratory of
the Institute of Food and Environmental Hygiene of the
LLU VMF. Each smear was examined by light microscopy
at 400 and 1000 times magnification, counting 100-200
cells and determining their belonging to leukocyte popula-
tions: lymphocytes, macrophages, and polymorphonuclear
leukocytes (PMNL).
2.5. Immunocytochemical Analysis. A customized biotin-
streptavidin immunocytochemical method was performed
as described by Hsu et al. [14] to evaluate the expression of
inflammatory cytokines interleukin-1 (IL-1) and tumour
necrosis factor-alpha (TNF-α), inflammatory-inhibiting
cytokine interleukin-10 (IL-10), and antibacterial peptide
beta-defensin-2 (BD-2) expression, as well as apoptosis
marker caspase-6 in milk. A preparation of a specimen and
placing of milk sediment on glass slides was performed at
the Microbiology Laboratory of the Institute of Food and
Environmental Hygiene of the LLU VMF, but a staining of
the smears was carried out at the Morphology Laboratory
of the Institute of Anatomy and Anthropology at Riga Stra-
dins University. The following primary antibodies were used
for immunocytochemical staining of the smears: rabbit poly-
clonal IL-1α (code AB17281, dilution ratio 1 : 200, Abcam,
UK) and IL-10 (code Ab34843, 1 : 400, Abcam, UK), goat
polyclonal beta-defensin-2 (code AF2758, 1 : 100, RD Sys-
tems, UK), rabbit monoclonal caspase-6 (code Ab52951, 1:
250, Abcam, UK) and rabbit polyclonal tumour necrosis
factor-alpha (code ab6671, 1 : 100, Abcam, UK), and biotin-
related secondary antibodies (LSAB+LINK, code K1015,
DakoCytomation, DK).
2.6. Milk Quality Studies. The examination of milk quality
was carried out at Dairy Laboratory Ltd. (Ulbroka, Latvia).
The number of somatic cells was determined by fluorooptoe-
lectronic cell counting using a Fossomatic FC somatic cell
counter (Foss A/S, DK) in accordance with the standard
LVS EN ISO 13366-2:2007 “Milk—Enumeration of somatic
cells—Part 2: Guidance on the operation of fluoro-opto-
electronic counters”. The determination of the total bacterial
count was carried out with the electronic device “BactoScan
FC” (FOSS Electric AS, DE). The determination of fat, lac-
tose, and protein content in milk (%) was carried out using
the infrared spectroscopy method in accordance with ISO
Standard 9622 :1999 “Whole milk. Determination of milk
fat, protein and lactose content-Guidance on the operation
of mid-infrared instruments.” The pH was measured using
a pH meter; the working principle of which is to measure
the electrical conductivity of the milk and display the result
converted into the corresponding pH value.
2.7. Statistical Analysis. Results were expressed as average ±
standard error. Comparisons of the dynamics of mean
parameters were performed by the Wilcoxon Signed Ranks
two-sample test. The Mann–Whitney U test was used for
comparisons between GLP 810 and control group parame-
ters. We also used a Chi-Square test to independently assess
whether two variables differ from each another. The Cra-
mer’s V test allowed us to assess the strength and relevance
of the relationship between two features that did not fit the
normal distribution or between two scale variables. In con-
trast, we used the Kendall’s (Kendall’s tau-b) correlation
coefficient to measure the relationship between two ordinal
variables [15, 16]. For assessment of the expression of cyto-
kines, BD-2, and caspase-6, the semiquantitative counting
method for a relative quantity of positive structures [17]
was used. The positive structures according to their quantity
into immunoreactive cells were divided into several groups:
(-) none, (+) a few, (++) average, and (+++) a lot. To com-
pare distribution of results obtained by means of immunocy-
tochemical methods, a relative frequency calculation model
was used [18]. Statistical significance was set at p < 0:05 for
all statistical analyses.
3. Results
3.1. Leukocyte Dynamics in Milk. Using milk leukocyte dif-
ferential counting, a significant increase in the number of
polymorphonuclear leukocytes (PMNL) was observed that
occurred both in the milk of the experimental (about 56-63%,
p < 0:001) and the control groups (about 45-63%, p < 0:01,
p < 0:05) following intramammary infusions, as shown in
Table 1. The increase in PMNL count continued until the
14th day and probably longer in the experimental group
mammary glands, while the number of PMNL was decreased
on the 14th day in the control group milk with no significant
difference from the baseline.
As shown in Table 1, the number of lymphocytes
increased significantly in the milk of the experimental group
(p < 0:001), whereas no significant changes (p > 0:05) in the
lymphocyte count were detected in the control group mam-
mary glands. The number of macrophages after infusions
diminished both in the milk of experimental (p < 0:001)
and control groups (p < 0:01). It was supposed that the abso-
lute number of macrophages had not changed noticeably,
because their percentage fraction had decreased due to the
parallel increase in PMNL and lymphocytes. Figure 1 shows
a typical view of milk smears of cows with high SCC on the
3rd day of the study.
In summary, after GLP 810 infusions, the alterations in
milk’s PMNL count (increase by 50-60%) as well as lympho-
cyte (increase by 60%) and macrophage (decrease by 65%)
count lasted during the entire observation, i.e., from the 3rd
day to the14th day. In the control group, the significant
changes in the distribution of cells (where the number of
PMNL had increased by 50-60% and the number of
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macrophages decreased by 30-75%) lasted until the 7th day
but had returned to baseline by the 14th day.
3.2. Expression of the Inflammatory Cytokines. Prior to the
infusions, the TNF-α immunoreactive cells, mainly macro-
phages, were found in the milk of both cow groups. These
cells were found to be present in small amounts at similar fre-
quencies (16-25%) without any correlation to the number of
SCC and pathogenic bacteria. As shown in Table 2, as soon as
the infusions of GLP 810 were started, the expression of
TNF-α in experimental mammary glands showed a general
tendency to increase by 2.3 times and in the following period
from the 3rd to the 7th day remained unchanged.
The expression of TNF-α (see Figure 2) was significantly
higher in the samples with high SCC and high number of
pathogenic bacteria (more than 10 cfu × 103 mL−1) than that
in the samples with low SCC (p < 0:05). Besides, a TNF-α
release from immune cells from the 1st day was detected only
in those milk samples, where somatic cells comprised more
than 10% of PMNL and less than 10% lymphocytes.
After infusions of composition GLP 810, the expression
of IL-1 in immune cells showed a tendency to decrease
gradually, and on the 7th day, the IL-1 was found to be
approximately 80% less in the baseline group (see Table 2).
Throughout the study, IL-1 was detected only in those milk
samples of the experimental group, where S. aureus, Staphy-
lococcus spp. and bacteria belonging to the family Enterobac-
teriaceae including E. coli were isolated (1 d Cramer’s V
coeff. 0.827 and p < 0:005; 3 d Cramer’s V coeff. 0.659 and
p < 0:05). In contrast, when the pathogens were not isolated,
no expression of IL-1 in cells was detected.
As shown in Table 2, the expression of BD-2 in terms
of frequency and intensity in leukocytes in the milk of the
experimental group had already increased on the 3rd day,
but a significant increase was found on the 7th day, when
milk secretion of 80% (15/19) of the mammary glands
had been disturbed and most of the milk samples (18/19)
contained BD-2-positive cells (p < 0:01). BD-2-positive
immune cells in variable frequency in the milk samples of
the control group were also found, but the observed
changes were statistically insignificant.
The frequency and intensity of IL-10 expression in the
milk samples of the experimental group after GLP 810
infusions increased significantly (on the 3rd day, p < 0:05;
on the 7th day, p < 0:005) until each of the 19 experimen-
tal group milk samples contained IL-10-positive cells on
the 7th day. The expression of IL-10 showed a decreasing
trend (see Table 2) in the milk samples of the control
group, and on the 7th day, it was significantly lower in
comparison with the milk samples of the experimental
group (p < 0:05). The expression of IL-10 on the 1st day
was significantly higher in the milk samples with high
SCC (Kendall test 0.774 and p < 0:001).
As shown in Table 2, the change in caspase-6 expression
was low and statistically insignificant (p > 0:05) in both study
groups. Both the experimental (p < 0:005) and control
groups (p > 0:05) showed an expression of caspase-6 only
Table 1: Dynamics of milk differential somatic cell count.
Milk somatic cells Result
GLP 810 group (n = 19) Control group (n = 19)
1st d 3rd d 7th d 14th d 1st d 3rd d 7th d 14th d
PMNLc
Mean number of cells, % 18.9 43.1 50.8 53.2 23.2 42.5 63.7 37.8
Standard error of the mean 4.1 4.0 3.6 3.2 4.7 4.9 3.9 11.4
p value versus baselinea — ∗∗∗ ∗∗∗ ∗∗∗ — ∗∗ ∗ >0.05
p value between study groupsb >0.05 >0.05 >0.05 ∗ >0.05 >0.05 >0.05 ∗
Lymphocytes
Mean number of cells, % 15.0 34.2 29.1 27.3 15.7 17.8 21.7 16.3
Standard error of the mean 3.4 2.7 2.3 2.4 1.7 2.7 2.8 2.2
p value versus baselinea — ∗∗∗ ∗∗∗ ∗∗∗ >0.05 >0.05 >0.05 >0.05
p value between study groupsb >0.05 >0.05 ∗∗∗ ∗ >0.05 >0.05 ∗∗∗ ∗
Macrophages
Mean number of cells, % 66.1 22.7 20.0 19.5 61.2 39.8 14.7 46.0
Standard error of the mean 4.8 2.9 3.8 2.6 5.9 4.8 4.9 10.5
p value versus baselinea — ∗∗∗ ∗∗∗ ∗∗∗ >0.05 ∗∗ >0.05 >0.05
p value between study groupsb >0.05 >0.05 ∗∗ ∗∗ >0.05 >0.05 ∗∗ ∗∗
aBy Wilcoxon Signed Ranks test; bby Mann–Whitney U test; ∗p < 0:05, ∗∗p < 0:01; cPMNL: polymorphonuclear leukocytes; ∗∗∗p < 0:001.
Figure 1: Microscopic examination of milk somatic cells smear.
PMNL: polymorphonuclear leukocytes; LF: lymphocytes; MF:
macrophages; original magnification 1000x.
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Table 2: Cytokine expression in milk leukocytes.
GLP 810 group (n = 19)
TNF-α IL-1 IL-10∗ BD-2∗∗ Caspase-6
— + ++ — + — + ++ +++ — + ++ +++ — +
% of analysed samples
1st d 84 16 0 79 21 63 11 26 0 37 47 16 0 75 25
3rd d 63 37 0 84 16 16 53 26 5 21 53 26 0 74 26
7th d 63 37 0 95 5 0 37 58 5 5 47 37 11 89 11
Control group (n= 4)
1st d 75 25 0 100 0 50 25 25 0 25 50 25 0 75 25
3rd d 75 0 25 100 0 50 50 0 0 50 25 25 0 75 25
7th d 50 50 0 100 0 25 75 0 0 25 75 0 0 100 0
The positive structures according to their quantity in immunoreactive cells: (-) none, (+) a few, (++) average, and (+++) a lot. ∗Statistically significant
differences in the GLP 810 group versus baseline value on the 3rd day p < 0:05 and on the 7th day p < 0:005; ∗∗statistically significant differences in the GLP




Figure 2: Expression of cytokines in milk by biotin-streptavidin immunocytochemistry method: (a) TNF-α, 100x; (b) TNF-α, 400x; (c) IL-1, 400x;
(d) IL-10, 400x; (e) BD-2, 400x; (f) caspase-6, 400x. The brown colour in the cytoplasm and cell nuclei indicates a positive presence of cytokines.
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in those milk samples where the SCC was more than 200 ×
103 cells mL-1. A statistically significant close relationship
was also observed between the amount of caspase-6-
positive cells and the number of PMNL inmilk, because obvi-
ously more leukocytes meant more caspase-6 expression in
the leukocytes (in the GLP 810 group p < 0:005, in the con-
trol group p < 0:05). Throughout the study, the release of this
enzyme in both study groups was found only in those milk
samples where the number of PMNL was at least 30% of
countable cells.
3.3. Bacteriological Examination. Prior to administration of
the composition GLP 810 in mammary glands, mastitis-
causing bacteria were present in 84.2% (n = 16/19) of all
experimental group mammary glands and in 47.4%
(n = 9/19) of control group mammary glands. Detected path-
ogens belonged to S. aureus and other bacteria of the genus
Staphylococci and the bacteria from Enterobacteriaceae fam-
ily, including E. coli., GLP 810 infusions on the 3rd study
day provided full bacteriological clearance in 10 out of 16
infected mammary glands (62.5%). Bacterial clearance in
the control group on the 3rd day was detected in 4 out of 9
infected mammary glands (44.4%). On the 7th study day, bac-
teriological clearance was diagnosed in 8 initially infected
mammary glands of the experimental group (50.0%) and in
5 mammary glands of the control group (55.5%) which was
a nonsignificant difference.
Furthermore, the total number of pathogenic bacteria
was examined. As it is shown on Table 3, a significant
decrease in the total number of pathogenic bacteria on the
3rd day by 87% (p < 0:05) and on the 7th day by 92%
(p < 0:05) in the GLP 810 group mammary glands was
observed.
Throughout the study, the total number of pathogenic
bacteria did not change remarkably (p > 0:05) in initially
low SCC and control cow group mammary glands,
whereas the significant decrease in the number of patho-
genic bacteria by 97% (p < 0:05) was detected in initially
infected experimental cow group mammary glands with
high SCC.
As shown in Figure 3, the number of S. aureus bacteria
in the milk of the experimental group (n = 4) on the 1st
day averaged 54:3 ± 7:9 cfu × 103 mL−1. Two days after
the first infusion of the composition GLP 810, S. aureus
was not detected in any milk samples, but on the 7th
day, a low amount of this pathogen was isolated only in
one milk sample (10.0 cfumL-1-99.9% less than on the 1st
study day).
The average number of Enterobacteriaceae microorgan-
isms is significantly reduced only in the milk samples of the
GLP 810 study group (p < 0:001), but the average number
of Staphylococcus spp. is significantly decreased in the milk
both in the experimental (p < 0:001) and in the control
groups (p < 0:001, p < 0:01) (see Figure 3).
Table 3: Dynamics of the total number of pathogenic bacteria.
Result
GLP 810 group (n = 19) Control group (n = 19)
1st d 3rd d 7th d 1st d 3rd d 7th d
Mean number of pathogenic bacteria, cfu × 103 mL−1 50.7 6.8 4.1 13.2 9.8 18.2
Standard error of the mean 29.0 4.4 1.9 5.9 7.8 1.1
p value by Wilcoxon Signed Ranks test (versus baseline) — 0.015∗ 0.049∗ — 0.184 0.244









































Figure 3: Dynamics of the number of mastitis-causing bacteria in milk: S. aureus (white bar), Enterobacteriaceae (black bar), Staphylococcus
spp. (gray bar); ++p < 0:01, +++p < 0:001 versus baseline value; ∗p < 0:05, ∗∗∗p < 0:001 versus 3rd day value; error bars indicate 95%
confidence intervals of the mean values.
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3.4. Evaluation of Milk Quality Indicators. In general, a rapid
increase in the SCC was detected in the milk of the experi-
mental group 48 hours after the 1st and 3rd infusions of
GLP 810 while SCC dynamics in the control group mam-
mary glands was statistically insignificant throughout the
study period. The increase in SCC occurred mainly in healthy
mammary glands (with low SCC on the 1st day) (p < 0:01)
both in the experimental and the control study groups, while
the SCC did not change remarkably in the milk from
inflamed mammary glands as shown in Figure 4.
The amount of lactose in the milk of the GLP 810 study
group significantly decreased from 4.7% on the 1st day to
4.1% on the 3rd day, and on the 7th study day, the lactose con-
tent was still significantly reduced (p < 0:001), i.e., by 4.2%
(see Figure 5). The milk protein content after infusions did
not change significantly. The milk fat content in the experi-
mental group had significantly increased by the 3rd day (from
1.6% to 2.4%; p < 0:05), but the control group expressed no
significant change (see Figure 5).
3.5. The Bovine Health and Changes in the Milk
Consistency. Visual changes in the milk consistency, i.e.,
a small number of flakes or clots, were observed every
day during the first week of the study. Significantly more
frequent changes were found to be in the milk obtained
from the experimental group cows from the 3rd to the
6th day of the study. It was found that the formation of
flakes and clots was significantly influenced by the milk
pH value (p < 0:005) since they were only observed in
milk samples with a pH range of 6.40-6.52, that is, lower
than the average in the group. In addition, the changes in
the milk consistency were probably due to the increased
activity of leukocytes in the milk, as almost all of the

































































Figure 4: Dynamics of somatic cell count in the milk from healthy (a) and inflamed (a) mammary glands. GLP 810 group (white bar), control
group (black bar); ∗p < 0:05, ∗∗∗p < 0:001 (between study groups); +p < 0:05, ++p < 0:01 (versus baseline value); error bars indicate 95%





































































Figure 5: Milk fat, lactose, protein, and pH dynamics in milk. GLP 810 group (white bar), control group (black bar); ∗p < 0:05, ∗∗p < 0:01,
∗∗∗p < 0:001 (between study groups); +p < 0:05, ++p < 0:01, +++p < 0:001 (between days); error bars indicate 95% confidence intervals of
the mean values.
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had also high SCC (more than 200 × 103 cells mL-1)
(p < 0:001).
4. Discussion
The protection of the mammary gland against infections is
provided by coordinated cooperation between nonspecific
or innate and specific or acquired immune mechanisms.
Consequently, the milk contains, either permanently or tem-
porarily, a variety of cellular and humoral components that
are involved in the immune response, thus making milk a
biologically active product. In order to evaluate the effect of
the immunomodulatory composition GLP 810 on the func-
tional state of the bovine nonspecific cellular immune system
locally in the mammary glands, we evaluated the number of
leukocyte populations. The effect of the composition GLP
810 on the number of leukocytes and their populations as
well as the lymphocyte subpopulation surface CD markers
in the bovine peripheral blood is discussed previously by
Gulbe with coauthors [19].
The present study revealed that applying intramamma-
rily the immunomodulatory composition GLP 810 in cows
with subclinical mastitis causes an activation of the local non-
specific cellular and the nonspecific humoral immune
response, which results in limitation of growth of pathogenic
bacteria in the mammary glands. In addition, we found that
by GLP 810, the proposed immunomodulation was balanced,
including the simultaneous migration of phagocytic cells to
the udder tissue and the release of anti-inflammatory factors,
providing controlled activation of the innate immunity. The
observed immune activity included both the nonspecific cel-
lular response and reactivity of nonspecific humoral factors
between the 3rd and 14th days of the study.
Alnakip with coauthors stated [20] that leukocytes are
permanently present in the mammary gland environment
as they aid in the restructuring of the udder tissue during
involution (i.e., apoptosis) or after inflammation and also
provides immediate immune response in case of invasion
of pathogenic bacteria while PMNL are the first recruited
immune cells from blood to sites of infection in the
mammary gland. As discussed elsewhere [21], the migra-
tion of PMNL during intramammary infection results in
an increase of SCC with the aim to phagocytose the bacte-
ria and to produce molecules of reactive oxygen and anti-
microbial peptides capable to eliminate broad spectrum of
mastitis causing bacteria.
As the significant increase in the number of PMNL
occurred in the milk after the treatment with GLP 810,
whereas the total number of leukocytes (as described on
manuscript by [19]) and the number of segmented neutro-
phils (as shown in Table 3, [22]) in the peripheral blood did
not significantly differ from the baseline and fell within the
physiological norm throughout the study period in the exper-
imental group, it may be concluded that the interaction of
PMNL between the peripheral blood and the milk is indica-
tive of the leukocyte-compensated proliferation in the mam-
mary glands. On the other hand, the absolute number of
segmented leukocytes in the blood of the control cow group
had a significant increase on the 3rd day exceeding the phys-
iological norm while the relative amount of these leukocytes
in the control milk exceeded the physiological norm at all
times during the study [22].
Several authors [23–25] have shown that the phagocytic
activity of the circulating blood neutrophils and macro-
phages increases after an application of probiotic lactic acid
bacteria into mammalian organisms through their immuno-
modulatory properties. Probably, our study contradicts this
fact, since the number of macrophages after infusions signif-
icantly diminished both in the milk of the experimental and
the control groups. Furthermore, no remarkable changes in
the total number of macrophage representative CD14+ cells
were detected in the cow blood [19]. It is considered that
the main function of macrophages is to develop substances
that promote the local inflammation, thus stimulating
phagocytic and bactericidal activity of PMNL, but phagocy-
tosis is not the primary task of macrophages. The growing
macrophage activity after infusions of GLP 810 is indicated
by cytokine dynamics that is described further in the manu-
script. Though we supposed that the absolute number of
macrophages had not changed noticeably, their percentage
fraction had decreased due to the parallel increase in PMNL
and lymphocytes.
We observed that GLP 810 had a significant effect on
lymphocyte activity in vivo indicated by the significant
increase in the number of lymphocytes in the cow milk of
the experimental group. Taking into account the results
described previously [19], which the number of lymphocytes
in the cow blood was significantly decreased after the start of
GLP 810 infusions, it suggests a short-term noncompensated
lymphocyte migration from the peripheral blood to the
mammary gland.
Using milk leukocyte differential counting, we observed
that the inflammatory reactions in the mammary glands were
long-lasting because of the increase in PMNL and lympho-
cyte count, but, at the same time, the decrease in macrophage
count lasted until the 14th day after GLP 810 infusions.
To measure the progress of inflammation in the mam-
mary glands, immunoreactive cells were labelled and the
expression of nonspecific humoral factors—interleukin-1
(IL-1), tumour necrosis factor-alpha (TNF-α), interleukin-
10 (IL-10), beta-defensin-2 (BD-2), and caspase-6—was
identified in milk leukocytes.
As discussed elsewhere [21, 26–28], IL-1 and TNF-α
are major inflammatory cytokines and are involved in
both local and systemic immune responses through stimu-
lating neutrophil leukocyte chemotaxis from the peripheral
bloodstream to the mammary tissue where they arrive sev-
eral minutes after the onset of infection. Bannerman [29]
report that the presence of TNF-α was not detected in
the healthy mammary glands.
At the start of the study, prior to the infusion of prepara-
tion, the TNF-α-immunoreactive cells, mainly macrophages,
were found in the milk of both cow groups. These cells were
found to be present in small amounts at similar frequencies
(16-25%), without any correlation to a number of SCC and
pathogenic bacteria. When starting the infusion of GLP
810, the expression of TNF-α in the experimental mammary
glands increased in general by 2.3 times and in the following
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period from the 3rd to the 7th days remained unchanged at
high levels, indicating the importance of this cytokine in
maintaining inflammation; that is, maintaining PMNL activ-
ity, as the number of PMNLs in milk had significantly ele-
vated during the period from the 3rd to the 7th. It is known
that neutrophils are the major producers of TNF-α during
inflammation. We revealed that the expression of TNF-α
was significantly higher in the samples with high SCC (aver-
age 3:4 ± 0:3 × 10−6 cells mL-1) than in the samples with low
SCC (average 72:0 ± 8:4 × 10−3 cells mL-1). Besides, cytokine
release from immune cells from the 1st day was detected only
in those milk samples where somatic cells comprised more
than 10% of PMNL and lymphocytes—less than 10%. Such
a leukocyte distribution in milk characterizes an infected
mammary gland as demonstrated by Alhussien et al. [30].
IL-1 likewise TNF-α is an inflammatory cytokine, but IL-
1 involvement in mastitis pathogenesis is not decisive and its
significance is influenced by the type of infectious agent as
discussed by Alluwaimi [27] and Shuster and Kehrli [31].
After infusions of GLP 810, the expression of IL-1 in immune
cells was gradually reduced, and on the 7th day, it was about
80% less than in the baseline readings. IL-1 release is thought
to be reduced due to (1) a decrease in macrophages, (2) an
increased anti-inflammatory cytokine IL-10 releases, and
(3) an increased activity of an apoptosis.
The apoptosis in the mammary glands is indicated by the
increase in the expression of caspase-6 immune-reactive cells
on the 3rd day by about 60% and by the decrease in the num-
ber of macrophages by an average of 65-70% from the 3rd to
the 7th days. Other authors [27, 32] also confirm that the
main distributors of IL-1 are monocytes in the blood and
macrophages in the milk, but in a case of apoptosis, the
amount of IL-1 decreases.
Beta-defensin-2 (BD-2) is characterized by bactericidal
effects on pathogenic microorganisms and immunomodula-
tory action within both specific and nonspecific immunity.
As previously described by Luenser and Ludwig [33] and
Meade et al. [34], beta-defensins promote broad-spectrum
leukocyte chemotaxis to the inflammatory site.
The observed increase in the expression of BD-2 in milk
leukocytes after GLP 810 infusions suggests its significant
role in the elimination of pathogenic bacteria, as well as in
promotion of PMNL and lymphocyte migration to the mam-
mary glands. The milk obtained on the 7th day of research
was characterized also by the lowest total number of condi-
tionally pathogenic bacteria, the lowest number of S. aureus,
and the bacteria from Enterobacteriaceae family and the
Staphylococcus spp.
Asadullah et al. [35] and Bannerman [29] stated that IL-
10 plays a key role in inhibiting inflammation and its action
has a protective effect on limiting tissue damage and promot-
ing tissue renewal after infections. We also detected the sig-
nificant increase in the IL-10 expression in the milk of the
experimental group. Furthermore, the role of IL-10 in reduc-
ing inflammation is confirmed by the fact that the expression
of this immunity-regulating cytokine was significantly higher
in the milk with elevated somatic cell count (Kendall coeff.
0.774, p < 0:001) and elevated total bacterial count (Kendall
coeff. 0.676, p = 0:005). Our study proved that IL-10 activity
in the cow mammary glands of the experimental group pro-
vided a balanced inflammatory response, which included the
activation of the cellular immunity locally in the mammary
glands, and lasted until the 14th study day (or 9 days after
the last infusion) resulting in a decrease in the number of
pathogenic bacteria and number of somatic cell count.
During the study, we observed that after GLP 810 infu-
sions, the number of pathogenic bacteria in milk samples sig-
nificantly decreased by 87%–92% (p < 0:01) because of the
antibacterial activity of the applied composition. The anti-
bacterial activity of lactic acid, lysozyme, and probiotics was
described elsewhere [8, 36–38], but studies are missing about
the action of these natural substances in vivo after it is intro-
duced in the udder. According to Panwar [39], Oliver and
Wells [40], and Wang et al. [41], lysozyme and lactic acid
cause physiological and morphological changes in bacterial
cells that lead to bacterial growth inhibition and cell death.
As the authors state, the hydrolysis products that originate
from bacterial cell walls after lysozyme action are capable of
enhancing immunoglobulin A secretion, macrophage activa-
tion, and rapid clearance of bacterial pathogens. And we
hypothesized that also glycopeptides promote activation of
immunity through macrophages, in order to activate T and
B lymphocytes—the major cellular components of the adap-
tive immune response as it is described previously by Gulbe
et al. (2016).
To evaluate the effect of immunomodulators on the qual-
ity of milk, analyses of the somatic cell count, pH value of the
milk, and the amount of nutritional content (fat, lactose, and
protein) were detected. Firstly, the rapid increase in the
somatic cell count in the experimental group’s milk after
GLP 810 infusions was observed similarly as in the other
studies in cows about intramammary application of bioactive
preparations of Lactobacillus origin [42] and other sub-
stances with immunomodulatory properties such as TNF
[43], recombinant bovine CD14 protein [44], and lactoferrin
[5]. We found out that intramammary infusion with GLP
810 caused the increase in quarter milk SCC mainly because
of an increase in SCC of initially uninfected quarters with low
SCC (p < 0:01). The SCC dynamics in the control group
mammary glands was statistically insignificant. Our observa-
tions are partially supported by the findings of Wellnitz et al.
[45] that 0.9% NaCl infusion does not lead to a significant
increase in quarter milk SCC.
Hence, a somatic cell count response after infusions of
immunomodulatory substances is beneficial, even irreplace-
able; the activity of leukocytes may result in decreased milk
synthesis and the amount of milk-specific ingredients, as well
as increased enzymatic activity of the milk, which is destruc-
tive to milk proteins and fats. However, our observations did
not confirm either the loss of milk synthesis or the decrease
in the amount of milk components after the infusion of prep-
arations, except for the amount of lactose. Considering that
infusions of GLP 810 did not lead to a destruction of nutri-
ents in the milk, we conclude that infiltration of neutrophils
in the mammary gland tissues was of moderate intensity.
During the study, we did not find any deterioration in the
clinical condition of cows (including body temperature, milk
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yield, and appetite), and the clinical state of mammary
glands were without pathological changes (such as swell-
ing, heat, hardness, redness, or pain). However, after infu-
sions of GLP 810, a small number of flakes or clots were
observed. Clots in the milk are usually the result of a deg-
radation of the cellular structure of casein. The authors
[46] report that casein loses its stability when the milk
pH is at pH4.6 or lower. However, our results do not con-
firm this possibility, since the pH value in any of the ana-
lysed milk samples was not lower than 6.2 and the protein
content of milk did not change substantially during the
study. It is possible that the formation of clots and flakes
following the administration of the composition GLP 810
into mammary glands has led to somatic cell-derived pro-
teases that can cause hydrolysis of beta casein and subse-
quent proteolysis [47]. In this case, however, the activity
of proteases in the milk glands during the study has been
low because it was observed only focally.
5. Conclusions
The results of this study have proved that the intramam-
mary use of GLP 810 in cows can activate both the local
nonspecific cellular and the humoral immune body
response, which results in limitation of pathogenic bacteria
growth in the mammary glands. In addition, we found that
the immunomodulation proposed by composition GLP 810
was balanced and involved a simultaneous migration of
phagocytic cells to the udder tissue and a release of anti-
inflammatory factors, thus providing controlled activation
of cellular immunity in the range of physiological norm
between the 3rd and 7th days.
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